The effect of insulin on response to intravitreal anti-VEGF injection in diabetic macular edema in type 2 diabetes mellitus

Rajya L. Gurung, Liesel M. FitzGerald, Ebony Liu, Bennet J. McComish, Georgia Kaidonis, Bronwyn Ridge, Alex W. Hewitt, Brendan Jt Vote, Nitin Verma, Jamie E. Craig, Kathryn P. Burdon

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To assess whether insulin therapy impacts the effectiveness of anti-vascular endothelial growth factor (anti-VEGF) injection for the treatment of diabetic macular edema (DME) in type 2 diabetes mellitus. Methods: This was a retrospective multi-center analysis. The best-corrected visual acuity (BCVA) at 12 months, BCVA change, central macular thickness (CMT), CMT change, and cumulative injection number were compared between the insulin and the oral hypoglycemic agent (OHA) groups. Results: The mean final BCVA and CMT improved in both the insulin (N = 137; p < 0.001; p < 0.001, respectively) and the OHA group (N = 61; p = 0.199; p < 0.001, respectively). The two treatment groups were comparable for final BCVA (p = 0.263), BCVA change (p = 0.184), final CMT (p = 0.741), CMT change (p = 0.458), and the cumulative injections received (p = 0.594). The results were comparable between the two groups when stratified by baseline vision (p > 0.05) and baseline HbA1c (p > 0.05). Conclusion: Insulin therapy does not alter treatment outcomes for anti-VEGF therapy in DME.

Original languageEnglish
Article number94
Number of pages9
JournalBMC Ophthalmology
Volume22
Issue number1
DOIs
Publication statusPublished - 28 Feb 2022

Keywords

  • Anti-VEGF
  • Central macular thickness
  • Diabetic macular edema
  • Insulin
  • Visual acuity

Fingerprint

Dive into the research topics of 'The effect of insulin on response to intravitreal anti-VEGF injection in diabetic macular edema in type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this